We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
Read MoreHide Full Article
We expect Eli Lilly and Company (LLY - Free Report) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.
So far this year, Lilly’s share price has improved 1.7% as against a decrease of 1.6% for the Zacks-classified Large-Cap Pharma industry.
Lilly’s earnings performance has been mixed with earnings surpassing expectations in two of the last four quarters, while missing in the other two, bringing the average negative surprise to 2.05%.
Let’s see how things are shaping up for this quarter.
Factors at Play
New products likeTrulicity, Cyramza, Taltz and Jardiance supported the top-line in the third quarter. We expect the trend to continue in the fourth quarter as well.
However, sales of Alimta, Cymbalta and Zyprexa are likely to decline. Lower demand in the U.S. due to competitive pressure from immuno-oncology agents has mainly hurt Alimta sales. Meanwhile, the loss of exclusivity is affecting sales of Cymbalta and Zyprexa.
Further, we expect marketing, selling and administrative as well as R&D expenses to continue to increase, which will again exert pressure on margins.
We remind investors that in early Dec 2016, the FDA approved Lilly’s request to add the cardiovascular (CV) indication to its type II diabetes drug Jardiance’s label. With about 50% of deaths in type II diabetics resulting from CV disease, the latest data addition is expected to improve Jardiance’s sales substantially.
Meanwhile, Basaglar - Lilly and partner Boehringer Ingelheim’s follow-on insulin to Sanofi’s blockbuster drug, Lantus- was launched in the U.S. in Dec 2016. Also, in the same month, Lilly announced the FDA approval of an extended-release formulation of its diabetes drug, Synjardy.
Meanwhile, in October, Lilly’s pipeline candidate, olaratumab received accelerated approval in the U.S. to be used in combination with doxorubicin for the treatment of soft tissue sarcoma. The drug will be sold under the trade name Lartruvo. The company is also anticipating an approval for its rheumatoid arthritis candidate, baricitinib, this year, which would bolster its top line.
Though the positive impact of these regulatory updates will be negligible in the to-be-reported quarter, these should boost sales and profits significantly in 2017
This explains the better-than-expected financial guidance for 2017 provided by Lilly in Dec 2016.
Note that last week, Lilly announced that it has received a favorable ruling in a lawsuit against Teva Pharmaceutical Industries Limited (TEVA - Free Report) related to the infringement of a vitamin regimen patent for Alimta by the U.S. Court of Appeals for the Federal Circuit. We expect management to provide further light on the issue at the fourth quarter conference call.
What Our Model Indicates
Our proven model shows that Lilly is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen and Lilly has the right mix.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate ($1.01 per share) and the Zacks Consensus Estimate (99 cents per share), is +2.02%. This is a meaningful indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Lilly has a Zacks Rank #2.
The combination of Lilly’s favorable Zacks Rank and positive ESP makes us confident of an earnings beat in its upcoming release.
Conversely, the Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks to Consider
Other stocks in the pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank are:
Vertex Pharmaceuticals, Inc. (VRTX - Free Report) has an Earnings ESP of +400.0% and a Zacks Rank #3. The company is scheduled to release results on Jan 25.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Eli Lilly's (LLY) Earnings Surpass Estimates in Q4?
We expect Eli Lilly and Company (LLY - Free Report) to beat expectations when it reports fourth-quarter and full-year 2016 earnings results on Jan 31, before market opens.
So far this year, Lilly’s share price has improved 1.7% as against a decrease of 1.6% for the Zacks-classified Large-Cap Pharma industry.
Lilly’s earnings performance has been mixed with earnings surpassing expectations in two of the last four quarters, while missing in the other two, bringing the average negative surprise to 2.05%.
Eli Lilly and Company Price and EPS Surprise
Eli Lilly and Company Price and EPS Surprise | Eli Lilly and Company Quote
Let’s see how things are shaping up for this quarter.
Factors at Play
New products likeTrulicity, Cyramza, Taltz and Jardiance supported the top-line in the third quarter. We expect the trend to continue in the fourth quarter as well.
However, sales of Alimta, Cymbalta and Zyprexa are likely to decline. Lower demand in the U.S. due to competitive pressure from immuno-oncology agents has mainly hurt Alimta sales. Meanwhile, the loss of exclusivity is affecting sales of Cymbalta and Zyprexa.
Further, we expect marketing, selling and administrative as well as R&D expenses to continue to increase, which will again exert pressure on margins.
We remind investors that in early Dec 2016, the FDA approved Lilly’s request to add the cardiovascular (CV) indication to its type II diabetes drug Jardiance’s label. With about 50% of deaths in type II diabetics resulting from CV disease, the latest data addition is expected to improve Jardiance’s sales substantially.
Meanwhile, Basaglar - Lilly and partner Boehringer Ingelheim’s follow-on insulin to Sanofi’s blockbuster drug, Lantus- was launched in the U.S. in Dec 2016. Also, in the same month, Lilly announced the FDA approval of an extended-release formulation of its diabetes drug, Synjardy.
Meanwhile, in October, Lilly’s pipeline candidate, olaratumab received accelerated approval in the U.S. to be used in combination with doxorubicin for the treatment of soft tissue sarcoma. The drug will be sold under the trade name Lartruvo. The company is also anticipating an approval for its rheumatoid arthritis candidate, baricitinib, this year, which would bolster its top line.
Though the positive impact of these regulatory updates will be negligible in the to-be-reported quarter, these should boost sales and profits significantly in 2017
This explains the better-than-expected financial guidance for 2017 provided by Lilly in Dec 2016.
Note that last week, Lilly announced that it has received a favorable ruling in a lawsuit against Teva Pharmaceutical Industries Limited (TEVA - Free Report) related to the infringement of a vitamin regimen patent for Alimta by the U.S. Court of Appeals for the Federal Circuit. We expect management to provide further light on the issue at the fourth quarter conference call.
What Our Model Indicates
Our proven model shows that Lilly is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen and Lilly has the right mix.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate ($1.01 per share) and the Zacks Consensus Estimate (99 cents per share), is +2.02%. This is a meaningful indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Lilly has a Zacks Rank #2.
The combination of Lilly’s favorable Zacks Rank and positive ESP makes us confident of an earnings beat in its upcoming release.
Conversely, the Sell-rated stocks (Zacks Rank #4 or 5) should never be considered going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Other Stocks to Consider
Other stocks in the pharmaceuticals sector that have both a positive ESP and a favorable Zacks Rank are:
Merck & Co., Inc. (MRK - Free Report) is expected to release results on Feb 2. The company has an Earnings ESP of +1.14% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex Pharmaceuticals, Inc. (VRTX - Free Report) has an Earnings ESP of +400.0% and a Zacks Rank #3. The company is scheduled to release results on Jan 25.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>